Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Daré Bioscience, Inc. (DARE)

1.04   -0.02 (-1.89%) 03-31 16:00
Open: 1.07 Pre. Close: 1.06
High: 1.0701 Low: 1.02
Volume: 297,446 Market Cap: 88(M)

Technical analysis

as of: 2023-03-31 4:17:55 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.25     One year: 1.34
Support: Support1: 0.95    Support2: 0.79
Resistance: Resistance1: 1.07    Resistance2: 1.14
Pivot: 1.01
Moving Average: MA(5): 1.03     MA(20): 1.02
MA(100): 1.03     MA(250): 1.1
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 68.9     %D(3): 54
RSI: RSI(14): 49.1
52-week: High: 1.65  Low: 0.81
Average Vol(K): 3-Month: 313 (K)  10-Days: 155 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ DARE ] has closed below upper band by 22.2%. Bollinger Bands are 54.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.08 - 1.09 1.09 - 1.09
Low: 1.01 - 1.01 1.01 - 1.02
Close: 1.05 - 1.06 1.06 - 1.07

Company Description

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Headline News

Fri, 31 Mar 2023
DARE BIOSCIENCE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K) - Marketscreener.com

Thu, 30 Mar 2023
Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update - Yahoo Finance

Thu, 23 Mar 2023
Daré Bioscience to Host Full-year 2022 Financial Results and ... - Benzinga

Mon, 13 Mar 2023
Dare Bioscience : March Investor Presentation - Marketscreener.com

Wed, 22 Feb 2023
Daré Bioscience Announces Start of a Phase 1 Study for its Potential ... - GlobeNewswire

Wed, 01 Feb 2023
Daré Bioscience to Participate in Three February Conferences - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 85 (M)
Shares Float 83 (M)
% Held by Insiders 1.9 (%)
% Held by Institutions 8.6 (%)
Shares Short 554 (K)
Shares Short P.Month 1,790 (K)

Stock Financials

EPS -0.35
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.31
Profit Margin (%) -245.5
Operating Margin (%) -247
Return on Assets (ttm) -31.2
Return on Equity (ttm) -84.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.01
Sales Per Share 0.11
EBITDA (p.s.) -0.3
Qtrly Earnings Growth 0
Operating Cash Flow -22 (M)
Levered Free Cash Flow -13 (M)

Stock Valuations

PE Ratio -3.06
PEG Ratio 0
Price to Book value 3.35
Price to Sales 8.82
Price to Cash Flow -3.99

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2017-07-19
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.